𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial

✍ Scribed by D. H. Miller; P. D. Molyneux; G. J. Barker; D. G. MacManus; I. F. Moseley; K. Wagner

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
163 KB
Volume
46
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Magnetic resonance imaging results of th
Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis
✍ David K. B. Li; Donald W. Paty 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

The PRISMS (Prevention of Relapses and Disability by Interferon-␤1a Subcutaneously in Multiple Sclerosis) trial was a doubleblind, randomized, multicenter, phase III, placebo-controlled study of interferon-␤1a in 560 patients from 22 centers in 9 countries with clinically definite or laboratory-supp

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro